摘要
目的考察微泵输注比阿培南延长给药时间治疗重症肺炎的疗效与安全性,并进行药物经济学评价。方法 58例重症肺炎患者随机分为3 h延长输注组(EI组)和0.5 h短时间输注组(TI组),分别给予比阿培南0.3 g,q12 h^q6 h,比较两组治疗效果,并应用最小成本法进行药物经济学分析。结果 EI组有效率为63.33%,平均成本为(4 057±296)元;TI组有效率为60.71%,平均成本为(5 624±308)元,EI组治疗成本明显低于TI组(P<0.05)。结论延长输注比阿培南治疗重症肺炎具有显著的药物经济学优势,值得推广应用。
Objective To study the efficacy and economic benefit of extended-infusion of biapenem in treatment of severe pneumonia. Methods 58 patients were divided into 3 h extended-infusion group （El） and 0.5 h intermit-infusion group （TI）, given biapenem 0.3 g, q12 h-q6 h, respectively.The clinical effect was compared, and the pharmacoeconomics was analyzed by the least cost analysis. Results The effective rate of EI group was 63.33%, and the average cost was （ 4 057±296） yuan. The effective rate of TI group was 60.71%, the average cost was （5 624±308 ） yuan. The cost of EI group was significantly lower than that of the TI group （P〈0.05）. Conclusion It has prominent superiority for extended-infusion of biapenem to treat severe pneumonia, deserving of popularization and application.
出处
《中国药物警戒》
2016年第1期50-51,56,共3页
Chinese Journal of Pharmacovigilance
基金
广西柳州市科协软科学研究项目(桂科协软20140107)
广西卫生和计划生育委员会自筹经费科研课题(Z2015164)
关键词
比阿培南
延长输注
重症肺炎
biapenem
extended-infusion
pharmacoeconomics
